Predictive and Therapeutic Implications of a Novel PLCγ1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer.
Raquel Cruz-DuarteCátia Rebelo de AlmeidaMagda NegrãoAfonso FernandesPaula BorralhoDaniel SobralLina M Gallego-PaezDaniel MachadoJoão GramaçaJosé VílchezAna T XavierMiguel Godinho FerreiraAna R MirandaHelder MansinhoMaria J BritoTeresa R PachecoCatarina AbreuAna Lucia-CostaAndré MansinhoRita FiorLuis CostaMarta MartinsPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our discoveries reveal the potential of PLCγ1 as a predictive biomarker for cetuximab responses and suggest an alternative therapeutic approach to circumvent PLCγ1-mediated resistance to cetuximab in patients with RAS WT mCRC. In this way, this work contributes to the development of novel strategies in the medical management and treatment of patients with mCRC.